Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1014Abstract typeOral
TALVEY (talquetamab) is a bispecific T-cell engaging antibody designed to target the CD3 receptor found on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D). The findings presented at the ASH 2023, from the first-ever study of a regimen combining a GPRC5D-targeted therapy and an immunomodulatory agent revealed that, in the Phase Ib MonumenTAL-2 trial, a group of 35 patients received treatment with subcutaneous TALVEY. Among them, 19 were administered TALVEY at a recommended dose of 0.8 mg/kg Q2W or 0.4 mg/kg QW with step-up doses, pl...
